Krabbe Disease Treatment Market Report 2026

The krabbe disease treatment market size has grown strongly in recent years. It will grow from $2.47 billion in 2025 to $2.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to improved awareness of rare neurodegenerative disorders, expansion of newborn screening initiatives, early clinical use of hsct therapies, growth in rare disease research funding, availability of supportive care treatments.

The krabbe disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.36 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing gene therapy clinical trials, rising investments in precision medicine for rare diseases, expansion of early diagnostic technologies, growing focus on disease-modifying treatments, increased regulatory support for orphan drugs. Major trends in the forecast period include increasing adoption of gene therapy approaches, rising use of early newborn screening programs, growing focus on early hsct intervention, expansion of supportive and symptomatic care protocols, increased research into enzyme replacement solutions.

The increasing implementation of newborn screening programs is expected to drive the growth of the krabbe disease treatment market in the coming years. Newborn screening programs are healthcare initiatives that test infants shortly after birth for potentially serious but treatable genetic, metabolic, and developmental disorders. The expansion of these programs is supported by advancements in medical technology, which allow for earlier and more accurate detection, enabling timely interventions to prevent severe health complications. Newborn screening facilitates the early identification of krabbe disease, allowing treatments such as stem cell transplantation to be administered before symptoms appear, improving patient outcomes and slowing disease progression. For example, in November 2023, the Michigan Department of Health and Human Services, a US-based state agency, reported that as of 2022, over 7.7 million infants had been screened, with more than 8,000 diagnosed with conditions from the NBS blood spot panel. Among the 100,176 infants screened in 2022, the majority were Michigan residents, with 322 (0.3%) diagnosed with a disorder. Therefore, the growing prevalence of newborn screening programs is driving the growth of the krabbe disease treatment market.

Major companies operating in the krabbe disease treatment market are concentrating on developing advanced gene therapy programs to enhance treatment efficacy and expand global accessibility. Gene therapy programs involve modifying or replacing genes within a patient’s cells to treat or prevent diseases. These therapies aim to correct genetic mutations by introducing, removing, or altering specific genes, offering potential cures for genetic disorders. For instance, in March 2024, Forge Biologics, a US-based gene therapy company, introduced FBX-101, an adeno-associated viral (AAV) gene therapy that received the Innovation Passport designation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). This designation enables FBX-101 to enter the Innovative Licensing and Access Pathway (ILAP), accelerating regulatory approval and market access for treatments targeting serious or life-threatening conditions. FBX-101 has shown promising safety and efficacy in early clinical trials and works by delivering a functional GALC gene to patients, aiming to improve outcomes for children affected by this rare, fatal neurodegenerative disease.

In November 2023, Ajinomoto Co., Inc., a Japan-based biotechnology and food company, acquired Forge Biologics Holdings, LLC for $554 million. Through this acquisition, Ajinomoto seeks to expand its presence in the gene therapy sector and strengthen its biopharma services business. The acquisition aligns with Ajinomoto’s ASV Initiatives 2030 Roadmap, which focuses on making healthcare a core growth area by integrating advanced gene therapy development and manufacturing capabilities. Forge Biologics Holdings LLC is a US-based provider of gene therapy for krabbe disease.

Major companies operating in the krabbe disease treatment market are Ajinomoto Co Inc, Passage Bio Inc, Magenta Therapeutics Inc, Gain Therapeutics Inc, M6P Therapeutics, Neurogene Inc, Greenwood Genetic Center, PreventionGenetics, MediciNova Inc, Polaryx Therapeutics Inc, Orchard Therapeutics Ltd, AVROBIO Inc, Bluebird Bio Inc, Regenxbio Inc, Homology Medicines Inc, Sangamo Therapeutics Inc, Editas Medicine Inc, CRISPR Therapeutics AG, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Company Limited, Amgen Inc, Biogen Inc, JCR Pharmaceuticals Co Ltd, Ultragenyx Pharmaceutical Inc.

North America was the largest region in the krabbe disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the krabbe disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the krabbe disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the krabbe disease treatment market by increasing costs of imported biologics, viral vectors, diagnostic reagents, and specialized medical equipment used in gene therapy, enzyme replacement therapy, and stem cell transplantation. North America and Europe are most affected due to reliance on cross-border biopharmaceutical supply chains, while Asia-Pacific faces higher costs for imported diagnostics and research tools. These tariffs are contributing to elevated treatment development costs and slower commercialization timelines. However, they are also encouraging localized biomanufacturing, regional clinical research infrastructure development, and domestic production of advanced therapeutics for rare genetic diseases.

The krabbe disease treatment market research report is one of a series of new reports that provides krabbe disease treatment market statistics, including krabbe disease treatment industry global market size, regional shares, competitors with a krabbe disease treatment market share, detailed krabbe disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the krabbe disease treatment industry. This krabbe disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Krabbe disease treatment refers to medical interventions aimed at managing symptoms and slowing the progression of Krabbe disease, a rare and often fatal genetic disorder that affects the nervous system. Treatments may include hematopoietic stem cell transplantation (HSCT), which is most effective when performed early, as well as supportive care such as physical therapy, seizure management, nutritional support, and pain relief.

The primary types of Krabbe disease treatment include medication, enzyme replacement therapy, gene therapy, and stem cell therapy. Medications, such as anticonvulsants and muscle relaxants, are used to manage symptoms like seizures and muscle stiffness to improve quality of life. Diagnosis is carried out using methods such as newborn screening and genetic testing, and treatments are distributed through channels including retail pharmacies, e-commerce, and hospital pharmacies. These therapies are applied across various forms of the disease, including infantile-onset, late-onset, and adult-onset Krabbe disease, and are used by end users such as hospitals, clinics, research centers, laboratories, and others.

The krabbe disease treatment market consists of revenues earned by entities providing services such as genetic counseling, enzyme activity testing, hematopoietic stem cell transplantation (HSCT), and supportive care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The krabbe disease treatment market also includes sales of viral vectors, infusion equipment, diagnostic kits, and neurological monitoring systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.